Differential regulation of the inducible nitric oxide synthase gene by estrogen receptors 1 and 2.

Estrogen has both rapid and longer term direct effects on cardiovascular tissues mediated by the two estrogen receptors, ESR1 and ESR2. Previous work identified that estrogen regulates the expression of inducible nitric oxide synthase (NOS2A) in vascular smooth muscle cells (VSMC). ESR2 knockout mice have vascular dysfunction due to dysregulation of NOS2A expression and these mice are hypertensive (Zhu et al. Science 2002 295 505-508). Here, we report studies to examine the differential regulation of NOS2A gene expression by ESR1 and 2. Immunoblotting and RT-PCR studies revealed that different VSMC lines expressed different levels of ESR1 and ESR2 protein and mRNA. VSMC from different vascular beds were studied, including aortic VSMC expressing ESR1 and radial (Rad) VSMC expressing ESR2. E(2) inhibited NO production and NOS2A protein expression in aortic VSMC. Human NOS2A promoter-reporter studies revealed suppression of NOS2A reporter activity by E(2) in aortic VSMC, and stimulation of NOS2A reporter activity by E(2) in Rad arterial VSMC. In heterologous expression studies of COS-7 cells lacking endogenous ER, E(2) treatment of COS-7 cells did not alter NOS2A reporter activity in the presence of ESR1, while reporter activity increased 2.3-fold in the presence of ESR2. Similar experiments in COS-7 cells using the selective estrogen receptor modulator raloxifene showed that raloxifene caused a reduction in NOS2A reporter activity with ESR1 coexpression and an increase with ESR2 coexpression. Rat VSMC expressing ESR2 but not ESR1 also showed increased NOS2A reporter activity with E(2) treatment, an effect lost when ESR1 was introduced into the cells. Taken together, these data support that hNOS2A transcription is regulated positively by ESR2 and negatively by ESR1 in VSMC, supporting differential actions of these two estrogen receptors on a physiologically relevant gene in VSMC.

[1]  J. Bienkowska,et al.  Estrogen Receptors α and β Mediate Distinct Pathways of Vascular Gene Expression, Including Genes Involved in Mitochondrial Electron Transport and Generation of Reactive Oxygen Species , 2007 .

[2]  M. Eren,et al.  Differential and Opposing Regulation of PAI-1 Promoter Activity by Estrogen Receptor &agr; and Estrogen Receptor &bgr; in Endothelial Cells , 2004, Circulation research.

[3]  X. Ni,et al.  Estrogen receptor-mediated down-regulation of corticotropin-releasing hormone gene expression is dependent on a cyclic adenosine 3',5'-monophosphate regulatory element in human placental syncytiotrophoblast cells. , 2004, The Journal of clinical endocrinology and metabolism.

[4]  M. Ohmichi,et al.  Both estrogen and raloxifene cause G1 arrest of vascular smooth muscle cells. , 2003, The Journal of endocrinology.

[5]  Carolyn L. Smith,et al.  Mechanistic Differences in the Activation of Estrogen Receptor-α (ERα)- and ERβ-dependent Gene Expression by cAMP Signaling Pathway(s)* , 2003, The Journal of Biological Chemistry.

[6]  R. Karas,et al.  The protective effects of estrogen on the cardiovascular system. , 2002, The New England journal of medicine.

[7]  John H. White,et al.  Diversity in the mechanisms of gene regulation by estrogen receptors. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[8]  J. Gustafsson,et al.  Abnormal Vascular Function and Hypertension in Mice Deficient in Estrogen Receptor β , 2002, Science.

[9]  J. Moss,et al.  Mitogen-activated Protein Kinases Mediate Activator Protein-1-dependent Human Inducible Nitric-oxide Synthase Promoter Activation* , 2001, The Journal of Biological Chemistry.

[10]  N. Weigel,et al.  8-Bromo-Cyclic AMP Induces Phosphorylation of Two Sites in SRC-1 That Facilitate Ligand-Independent Activation of the Chicken Progesterone Receptor and Are Critical for Functional Cooperation between SRC-1 and CREB Binding Protein , 2000, Molecular and Cellular Biology.

[11]  D. McDonnell,et al.  The Estrogen Receptor ␤-isoform (er␤) of the Human Estrogen Receptor Modulates Er␣ Transcriptional Activity and Is a Key Regulator of the Cellular Response to Estrogens and Antiestrogens* , 2022 .

[12]  J. Gustafsson,et al.  Estrogen receptor beta--a new dimension in estrogen mechanism of action. , 1999, The Journal of endocrinology.

[13]  D. Feinstein,et al.  Regulation of the expression of the inflammatory nitric oxide synthase (NOS2) by cyclic AMP , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  B. Katzenellenbogen,et al.  The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. , 1999, Molecular endocrinology.

[15]  F. Ross,et al.  Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD. , 1999, The Journal of clinical investigation.

[16]  J. Thomsen,et al.  The Orphan Nuclear Receptor SHP Inhibits Agonist-dependent Transcriptional Activity of Estrogen Receptors ERα and ERβ* , 1999, The Journal of Biological Chemistry.

[17]  J. Corton,et al.  Interaction of Estrogenic Chemicals and Phytoestrogens with Estrogen Receptor β. , 1998, Endocrinology.

[18]  D. Moore,et al.  Inhibition of estrogen receptor action by the orphan receptor SHP (short heterodimer partner). , 1998, Molecular endocrinology.

[19]  I. Yuhanna,et al.  Establishment of an immortalized fetal intrapulmonary artery endothelial cell line. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[20]  H. Majewski,et al.  17β-Estradiol reduces vasoconstriction in endothelium-denuded rat aortas through inducible NOS. , 1998, American journal of physiology. Heart and circulatory physiology.

[21]  A. Ray,et al.  Repression of interleukin‐6 gene expression by 17β‐estradiol: , 1997 .

[22]  A. Mügge,et al.  Contractile responses to histamine, serotonin, and angiotensin II are impaired by 17 beta-estradiol in human internal mammary arteries in vitro. , 1997, Pharmacology.

[23]  J. Gardin,et al.  Relationship of cardiovascular risk factors to echocardiographic left ventricular mass in healthy young black and white adult men and women. The CARDIA study. Coronary Artery Risk Development in Young Adults. , 1995, Circulation.

[24]  N. Schork,et al.  Sex‐Specific Determinants of Increased Left Ventricular Mass in the Tecumseh Blood Pressure Study , 1994, Circulation.

[25]  R. Karas,et al.  Human vascular smooth muscle cells contain functional estrogen receptor. , 1994, Circulation.

[26]  W. Kannel,et al.  Menopause and risk of cardiovascular disease: the Framingham study. , 1977, Annals of internal medicine.

[27]  J. Bienkowska,et al.  Estrogen receptors alpha and beta mediate distinct pathways of vascular gene expression, including genes involved in mitochondrial electron transport and generation of reactive oxygen species. , 2007, Molecular endocrinology.

[28]  Carolyn L. Smith,et al.  Mechanistic differences in the activation of estrogen receptor-alpha (ER alpha)- and ER beta-dependent gene expression by cAMP signaling pathway(s). , 2003, The Journal of biological chemistry.

[29]  J-A,et al.  Estrogen receptor (cid:1) – a new dimension in estrogen mechanism of action , 1999 .

[30]  D. McDonnell,et al.  The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. , 1999, Endocrinology.

[31]  J. Corton,et al.  Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. , 1998, Endocrinology.

[32]  D. H. Zhang,et al.  Repression of interleukin-6 gene expression by 17 beta-estradiol: inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-kappa B by the estrogen receptor. , 1997, FEBS letters.

[33]  J. Gustafsson,et al.  Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. , 1997, Science.

[34]  P. López-Jaramillo,et al.  The L-arginine: nitric oxide pathway. , 1993, Current opinion in nephrology and hypertension.